Variants of XXXX modify the efficacy of statin therapy and the risk of @entity65 .

@entity1 @entity2939 @entity2998 @entity8673 @entity19825 @entity453 @entity20235 @entity731 @entity65 @entity165
BACKGROUND: @entity731 is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the @entity2939 ( @entity2939 ), which are correlated with impaired innate immunity and with progression of @entity2998 , are also associated with @entity453 and predict the risk of @entity65 . METHODS AND RESULTS: Two polymorphisms of the @entity2939 gene ( @entity19825 and @entity20235 ) were determined in 655 @entity1 with angiographically documented @entity453 . All @entity1 participated in a prospective @entity165 -lowering trial evaluating the effect on @entity453 and were randomly assigned to either @entity8673 or placebo for 2 years. There were no significant differences between genetically defined subgroups with respect to baseline risk factors, treatment, or in-trial changes of lipid, lipoprotein, or angiographic measurements. Genotype was not associated with progression of @entity731 . In the @entity8673 group, 299Gly carriers had a lower risk of @entity65 during follow-up than noncarriers (2.0% versus 11.5%, P=0.045). Among noncarriers, @entity8673 reduced the risk of @entity65 from 18.1% to 11.5% (P=0.03), whereas among 299Gly carriers this risk was strikingly reduced from 29.6% to 2.0% (P=0.0002, P=0.025 for interaction). CONCLUSIONS: Among symptomatic @entity1 with documented @entity453 , the @entity2939 @entity19825 polymorphism was associated with the risk of @entity65 . This variant also modified the efficacy of @entity8673 in preventing @entity65 , such that carriers of the variant allele had significantly more benefit from @entity8673 treatment.
